Teva Pharmaceutical lowered its 2026 non-GAAP operating income outlook to $3.80 billion-$4.0 billion from $4.55 billion-$4.8 billion. The revision reflects an expected $700 million in IPR&D charges plus $75 million related to Ema. The cut to profitability guidance is a meaningful negative for the stock, though the impact is company-specific rather than sector-wide.
Teva Pharmaceutical lowered its 2026 non-GAAP operating income outlook to $3.80 billion-$4.0 billion from $4.55 billion-$4.8 billion. The revision reflects an expected $700 million in IPR&D charges plus $75 million related to Ema. The cut to profitability guidance is a meaningful negative for the stock, though the impact is company-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
